ALNY vs EBS · P/E 76, rev $2.25B vs rev $1.04B
Alnylam Pharmaceuticals Inc (ALNY) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ALNY revenue for 2024-12-31 was $2.25B. Net income was -$278.2M. Revenue was up 23.0% from 2023-12-31 to 2024-12-31. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. EBS currently screens at market cap $416.4M.
Not investment advice. Open the ALNY and EBS stock pages for the full models.
Not investment advice.